news
EMA human medicines committee (CHMP) meeting highlights, March 2022
The March meeting saw the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommend five medications for approval including a multiple myeloma gene therapy.
List view / Grid view
Biologics
news
Moderna launches two new mRNA vaccine programmes
The new mRNA vaccine programmes are aimed at the major causative agents of respiratory tract infections, respiratory syncytial virus (RSV), influenza and coronaviruses.
news
Lumen publishes details of spirulina biomanufacturing platform
In a new paper, Lumen Bioscience detailed how spirulina can be genetically engineered for to rapidly produce large quantities of biologic drugs.
news
VISIBLE aims to better understand experience of psoriasis for people of colour
Janssen has announced plans to initiate a large-scale study into the impact of psoriasis among black, Hispanic, Asian, indigenous and other people of colour.
news
Intravacc publishes GMP vaccine candidate manufacturing process
A new paper details the GMP manufacturing and formulation process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur.
news
New preventative medicine for COVID-19 authorised in UK
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has reported that Evusheld, developed by AstraZeneca, has been granted approval to help protect against the effects of COVID-19.
![Catalent logo on website through a magnifying glass [Credit: Pavel Kapysh/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Catalent-300x278.jpg)
![Catalent logo on website through a magnifying glass [Credit: Pavel Kapysh/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Catalent-e1647945626125.jpg)
news
Catalent invests $30 million to modernise biopharmaceuticals site
The completed modernisation of Catalent’s facility in Limoges, France, will support the development of early phase and small-scale commercial biologic drugs.
news
Is Aduhelm® of benefit to Alzheimer’s patients long-term?
New data shows that patients taking Aduhelm® (aducanumab-avwa) had significant reductions in tau and amyloid beta after nearly 2.5 years.
news
mRNA vaccine candidates for HIV enter Phase I trial
Will mRNA vaccines one day protect against HIV? Three investigational mRNA vaccines, all designed to combat HIV, have entered Phase I testing.
news
Could AAT be the answer to COVID-19 ARDS?
Clinical study finds alpha-1 antitryspin (AAT) reduces pro-inflammatory IL-6 and therefore may benefit COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS).
news
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, March 2022
EMA’s pharmacovigilance committee recommends product information updates for two COVID-19 vaccines - Janssen COVID-19 Vaccine and Moderna’s Spikevax.
news
New agreement makes “Africa’s own COVID-19 vaccine” a reality
Under a new agreement with J&J, Aspen SA Operations will be able to manufacture and make available Aspen-branded COVID-19 vaccines in Africa.
news
Trodelvy® improves breast cancer progression-free survival, finds study
Trodelvy® (sacituzumab govitecan-hziy) was found to significantly reduce the risk of disease progression or death in certain breast cancer patients.
news
Chikungunya vaccine candidate safe and immunogenic in Phase III
Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly.
news
PRIME scheme benefits drug development, finds EMA report
The report outlines the positive impact the EMA’s PRIority Medicines (PRIME) scheme has had on drug development for unmet medical need over the last five years.
